This inventor holds 20 USPTO granted patents, primarily in Monoclonal Antibodies. Top assignees: Oncogen, Oncogen Limited Partnership, Bristol-Myers Squibb Compnay. Active years: 1987-1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
10 out of 48 
5 out of 7 
4 out of 3,746 
Years Active: 1987-1999
Areas of Expertise:
Title: **The Innovations of Hans Marquardt: Pioneering Anti-CD6 Ligand Antibodies**
Introduction
Hans Marquardt, based in Mercer Island, WA, is a prominent figure in the field of biomedical research, holding an impressive portfolio of 20 patents. His work primarily focuses on the development and applications of antibodies related to CD6, contributing significantly to advancements in immunology and therapeutic treatments.
Latest Patents
Among his latest contributions are two remarkable patents. The first patent relates to anti-CD6 ligand antibodies. This invention addresses the interaction between CD6, which is present on various immune cells, including thymic epithelial cells and activated T cells, and its ligand. The methods described aim to inhibit this interaction effectively, thereby opening pathways for innovative therapeutic approaches. Additionally, another patent centers on the encoding sequence for the CD6 ligand. This patent details an isolated nucleic acid molecule that specifies the CD6 ligand, alongside methods for producing it and the constructs containing this nucleic acid, paving the way for further research and development in targeted therapies.
Career Highlights
Hans has had a noteworthy career, having worked with companies such as Oncogen and Oncogen Limited Partnership. His expertise in the field has enabled the development of critical innovations in medical research, which have the potential to lead to new treatments for various diseases.
Collaborations
Throughout his career, Hans has had the opportunity to collaborate with esteemed colleagues, including Mohammed Shoyab and George J Todaro. These collaborations have fostered an environment of shared knowledge and innovation, yielding significant advancements in their respective fields.
Conclusion
In summary, Hans Marquardt stands out as an influential inventor in the realm of biomedical research. His contributions, particularly in the area of anti-CD6 ligand antibodies, are poised to have a lasting impact on how immune responses are understood and manipulated for therapeutic benefits. His patents not only reflect his innovative spirit but also signify hope for future medical advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile